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S284 Poster Session Iaggressive chemotherapy and radiotherapy on future fertility are
being increasingly realized in males. To counteract such deleteri-
ous effects, we initiated a formal fertility preservation program in
2007 to increase access to sperm cryopreservation (SCP) services
at our institution. Here we analyze our program’s utility and pa-
tient data to provide insight into fertility preservation prior to
SCT.
Methods: An IRB-approved chart review was conducted on all male
pediatric patients older than 13 years who underwent SCT between
January 2008 and June 2010 at our institution. Patients given a fertil-
ity preservation consult were identified, and the semen parameters of
those subsequently banking sperm were obtained.
Results:During the study interval, 22 male pediatric patients met
our study criteria, of which there were 19 allo-transplants and 3
auto-transplants. 8/22 (36%) patients were given fertility preserva-
tion consults and 6/22 (27%) proceeded to SCP, a consult success
rate of 75% (Table 1). 6/13 (38%) patients with planned radio-
therapy were consulted, compared to 2/9 (22%) patients with no
planned radiotherapy. Of the 6 patients banking sperm, 3 banked
prior to chemotherapy while 3 banked after. The average semen
parameters of patients banking before chemo vs after chemo-
therapy were as follows: Volume 2.50 vs 1.50 ml; Concentration
30.7 vs 30.6 million/ml; Motility 36.7% vs 21.3%; Normal
Morphology 9.7% vs 3.5%. Thus, while patients who banked
after chemotherapy had sub-fertile semen parameters, their bulk
semen parameters were still adequate for cryopreservation. All
bulk semen parameters tended to improve as age at banking
increased.
Conclusions:The high fertility preservation consult success rate in-
dicates a large desire to preserve fertility in patients planning SCT.
While bulk semen parameters were adequate for cryopreservation
in patients after treatment, DNA damage resulting from chemother-
apy was not assessed. Although cryopreservation of some sperm is
preferred over none, ample literature supports the notion that che-
motherapy has a deleterious effect on fertilization and embryo devel-
opment outcomes. Thus, every effort should be made to
cryopreserve sperm prior to chemotherapy and radiation. Finally,
further initiatives are required to extend the opportunity of fertility
preservation to all SCT patients.
Table 1. Demographic Comparison of All SCT Patients vs.
Consulted Patients
All Patients (N 5 22) Consulted Patients (N 5 8)Year
2008 10 4
2009 9 3
2010 3 1Transplant Type
Allogenic 19 7
Autologous 3 1Ethnicity
Caucasian 12 5
African American 4 1
Hispanic 5 2
Other 1 0219
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Hospital readmissions increase healthcare cost and are a target
of ways to improve cost and quality of medical care. Patients (pts)
who undergo allogeneic hematopoietic progenitor cell transplant
require a high level of care and are often readmitted. Thirty-day
hospital readmissions following allogeneic HPCT, however, are
associated with poor survival. In this retrospective review, weevaluated our 30-day readmissions for allogeneic HPCT occur-
ring in 2010 at our institution. The analysis included pts who
were not only transplanted in 2010 but also those who had
been previously transplanted (ranging from 1994-2010), and later
hospitalized again in 2010 and subsequently readmitted within
30 days.
There were 83 total readmissions for allogeneic transplant pts
within 30 days of a prior hospitalization in 2010. Only 47 pts,
however, accounted for these readmissions and 19 (23%) pts
were admitted multiple times (range 2-5 times), accounting for
55 (66%) of the readmissions. Initial diagnoses for pts admitted
more than once included: 7 refractory NHL, 4 AML, 3 ALL, 2
MDS, 2 AA and 1 CML. Donor type included 4 UCB, 5 MUD
and 10 MSD. Fifty-two percent (n 5 10) had a CIBMTR trans-
plant co-morbidity index score of .2. Fifty-three (64%) of the
30d readmissions after allogeneic HPCT were due to infection
or unexplained fever, followed by 9 (11%) for symptoms related
to GVHD, 7 (8%) due to cardiac complications (CHF, arrhyth-
mias), and 14 (17%) others related to symptom management
(pain, nausea/vomiting, diarrhea not related to infection or
GVHD). Looking specifically at reasons for subsequent repeated
readmissions demonstrated a similar distribution with the majority
of re-hospitalizations being for infection or unexplained fever, fol-
lowed by symptom management, cardiac complications, and
GVHD. There were 13 deaths, all related to infection or compli-
cations from GVHD. Median time to death after readmission was
27 days (range, 0 to 96).
Readmissions for allogeneic HPCT are associated with worse
survival. In this retrospective review we have found that the ma-
jority of readmissions were from pts admitted multiple times.
About half of these pts were identified as having higher co-
morbidity index scores. Further prospective studies of readmission
trends in allogeneic transplant and identification of high risk pts
who may be susceptible to multiple readmissions may help de-
crease readmission rates, transplant outcomes, and improve overall
quality of care.220
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Background: The association between venous thromboembolism
(VTE) and hematologic malignancy is well established. However,
VTE after allogeneic hematopoietic cell transplantation (HCT) is
not well characterized. The management is not standardized and
varies between hematologists.
Methods: A total of 260 patients underwent allogeneic HCT at
the University of Iowa between 2004 and 2009. Patient’s data
were retrospectively abstracted from the electronic medical record
and bone marrow transplant database. We report the incidence,
characteristics, management and outcome of VTE following
allotransplant.
Results: Of 260 patients who underwent allogeneic HCT, 35
(13.5%) developed VTE events. The median time from transplant
to VTE diagnosis was 121 days (-3 to 1853 d). Twenty-two pa-
tients (63%) developed VTE during the first six months post allo-
transplant. Sixteen patients (47%) had central venous catheter
related VTE. At VTE diagnosis, six patients (17%) had active he-
matologic malignancy and 18 patients (51%) had active GVHD ($
grade III). The median platelet count at VTE diagnosis was 65
(5-676) x 106/mm3. Twenty-five patients (71%) received systemic
anticoagulation (17 heparin products VS 8 heparin followed by
warfarin). Eight of 25 patients (32%) who had anticoagulation
treatment received therapeutic dose of anticoagulant whereas 17
patients had prophylactic dose. Among 10 patients who did not
receive systemic anticoagulation treatment either due to clinical ac-
tive bleeding or severe thrombocytopenia, two underwent inferior
vena cava filter placement. Eight patients (32%) had hemorrhagic
complications during anticoagulation. The median anticoagulation
Table. Characteristics of Patients Who Developed VTE after Allotransplant: Early VS Late
Early VTE (#6 mo) Late VTE (>6 mo)
p-valueN 5 22 (%) N 5 13 (%)
Gender (M/F) 17/5 6/7 0.06
Median age at allotransplant, years (range) 56 (20-63) 55 (38-64) 0.88
Diagnosis required allotransplant 0.31
Acute Leukemia 13 (60%) 6 (46%)
Myelodysplastic Syndrome 4 (18%) 0 (0%)
Myeloproliferative Neoplasm 1 (4%) 3 (23%)
Non Hodgkin Lymphoma 2 (9%) 2 (15%)
Chronic Lymphocytic Leukemia 2 (9%) 1 (8%)
Multiple Myeloma 0 (0%) 1 (8%)
Past history of VTE prior to allotransplant 5 (23%) 4 (31%) 0.60
History of tobacco smoking 10 (46%) 6 (46%) 0.97
Atherosclerotic risk factors* 7 (32%) 4 (31%) 0.94
Conditioning regimen 0.15
Myeloablative 17 (77%) 7 (54%)
Reduced Intensity 5 (23%) 6 (46%)
Stem Cell source 0.62
Bone marrow 5 (23%) 2 (15%)
Peripheral blood 16 (73%) 11 (85%)
Cord blood 1 (4%) 0 (0%)
HCT-CI† 0.09
0 2 (9%) 3 (23%)
1-2 9 (41%) 1 (8%)
$3 11 (50%) 9 (69%)
ECOG Performance status at VTE diagnosis 0.12
0-2 13 (59%) 11 (85%)
3-4 9 (41%) 2 (15%)
Pharmacologic VTE prophylaxis 1 (4%) 0 (0%) 0.44
Time from allotransplant to VTE, days (range) 98 (-3 to 174) 393 (208 to 1853) <0.0001
Active hematologic malignancy at VTE 2 (9%) 4 (31%) 0.10
Active graft versus host disease ($grade3) 10 (46%) 8 (62%) 0.36
Central venous catheter related VTE 15 (68%) 1 (8%) 0.001
Median platelet count (x106/mm3) (range) 54 (5-193) 95 (26-676) 0.031
*Atherosclerotic risk factors - obesity (body mass index > 30%), hypertension, dyslipidemia, diabetes mellitus.
†Hematopoietic Cell Transplantation-Comorbidity Index.
Poster Session I S285duration was 53 days (range, 6-877 d). The reasons of treatment
discontinuation included complete clinical response (32%), clini-
cally significant bleeding (32%), progressive thrombocytopenia
(24%) or others (12%). Six patients (17%) subsequently developed
recurrent VTE and one of these occurred during anticoagulation.
Conclusion: VTE may be a more frequent complication of allo-
transplant than previously recognized. Treatment of VTE following
allotransplant is challenging due to patients’ complexity and poten-
tial complications. Prospective studies are warranted to establish the
appropriate strategies for prevention and management.221
NEW ONSET OF SEVERE ALLERGIC MANIFESTATIONS IN LONG TERM
SURVIVORS AFTER CORD BLOOD TRANSPLANTATION
Vaughan, L.A.1, Jagasia, M.1, Engelhardt, B.1, Hagaman, D.2,
McCarty, K.2, Kassim, A.1, Clifton, C.1, Lucid, C.1, Domm, J.3,
Greer, J.P.1, Frangoul, H.3, Savani, B.N.1 1Vanderbilt Medical Center,
Nashville, TN; 2Vanderbilt Medical Center, Nashville, TN; 3Vanderbilt
Medical Center, Nashville, TN
Background:Umbilical-cord-blood-transplantation (CBT) is an ef-
fective treatment for benign and malignant diseases. Late effects of
CBT are not well described in the literature. In this study, we present
our experience with new onset allergies after CBT.
Methods: After the first patient experienced new onset severe al-
lergy related to peanut exposure, all CBT patients at a single cen-
ter were prospectively followed for new allergy development.
Presence of allergy was defined as a positive skin test or by radio-
allergosorbent test (RAST). Symptomatic allergy requiring imme-diate attention with clinical manifestations also defined as allergic
disease.
Results: Fifty patients received CBT between March 2006 and
June 2011. The majority of patients (n 5 43) received CBT for
hematological malignancies. The median follow-up after CBT
was 445 days (range, 12-2022). Twenty eight (56%) patients un-
derwent myeloablative and 22 (44%) received reduced-intensity
conditioning regimen CBT. Acute GVHD (grade III-IV) occurred
in 14 (28%) and chronic GVHD occurred in 14 of 41 patients
(34%) surviving beyond 100 days. At the time of analysis, 30 pa-
tients were alive with 3 year actuarial survival of 55.5%; median
follow-up of surviving patients was 910 days (range, 68-2022).
The allergic syndrome developed in 5 patients, with Kaplan-Meier
cumulative probability of 18.467.6%. The median time to onset
of new allergy presentation after transplantation was 298 days
(range, 250 to 809). Severity and types of allergies described in
Table 1. Among 6 patients (2 with allergies), trends were seen
between tissue-homing Treg subsets at engraftment and the de-
velopment of peanut allergies with allergic individuals character-
ized by decreased CLA+ (skin-homing) Tregs (median, 3.22% vs.
1.12%; P 5 0.064) and increased a4b7+ (gut-homing) Tregs
(median, 22.0% vs. 41.0%; P 5 0.064) (no allergy vs. allergy,
respectively).
Conclusion: This observation is important as it has therapeutic im-
plications in long term survivors after CBT. Allergy development has
been linked to a delayed maturation of the immune system in several
different studies. Th2-biased immune reconstitution after CBT
could be the mechanism for allergy transfer via cytokines induced
IgE synthesis. Impairment of regulatory T-cells after CBT is be-
lieved to be also one contributing factor in allergic disease. Counsel-
ing of patients to this previously unknown complication of CBT is
recommended.
